FOLD №18 — [Sar6]-Selank: N-methylation of Gly-6 for endopeptidase resistance

Verdict: PROMISING | pLDDT 0.87 | Peptide: TKPRP[MeG]P

Mechanism of action

Selank (TKPRPGP) is a synthetic heptapeptide analogue of tuftsin with an appended C-terminal Pro-Gly-Pro (PGP) tripeptide. Its pharmacological effects — anxiolysis, nootropic activity, stress protection, and immunomodulation — are well-documented in rodent models and supported by a human neuroimaging study showing altered amygdala–temporal cortex functional connectivity within 5–20 minutes of intranasal administration (PMID:32342318). The most consistently supported mechanistic hypothesis is allosteric modulation of the GABA-A receptor system, inferred from gene-expression studies in rat frontal cortex (PMID:26924987) and neuroblastoma cells (PMID:28293190). Selank does not directly alter GABAergic gene expression in isolation but modulates the response to exogenous GABA, consistent with an allosteric rather than orthosteric mechanism. A discrete tuftsin receptor or neurotensin-like receptor has not been pharmacologically validated; receptor identity for the N-terminal TKPR pharmacophore remains an open question.

Performance applications

Based on the established Selank literature (not on any new data generated here), the parent peptide has demonstrated:

• Anxiolytic activity comparable to diazepam in morphine withdrawal models (PMID:36322304)
• Nootropic / memory-protective effects, including mitigation of ethanol-induced memory impairment via BDNF modulation in hippocampus and prefrontal cortex (PMID:31625062)
• Stress-protective and immunomodulatory activity, including normalization of cytokine profiles under chronic stress (PMID:32621722) and hepatoprotection (PMID:31243679)
• Demonstrated CNS penetration in humans via intranasal route, with fMRI-detectable effects within minutes (PMID:32342318)

The [Sar6] modification is hypothesized to extend the duration of these effects by protecting the peptide backbone from endopeptidase degradation — not to alter the pharmacodynamic profile itself. Whether prolonged exposure translates to greater efficacy is genuinely uncertain: dose-response data for native Selank suggest a ceiling effect at ~300 µg/kg, raising the possibility that receptor saturation limits the benefit of extended residence.

Modification rationale

Selank's C-terminal PGP tripeptide is understood to be the primary stability-conferring element relative to native tuftsin, but the specific enzymatic vulnerabilities of the intact Selank backbone have not been mapped in published work. The Pro-Gly bond within PGP is a canonical substrate motif for prolyl-oligopeptidase (POP) and related post-proline endocleaving serine proteases, which recognize and hydrolyze amide bonds following proline residues. This represents a distinct and orthogonal degradation route from the C-terminal exopeptidase vulnerability addressed by amidation in Fold #8.

N-methylation of the scissile amide nitrogen — converting Gly-6 to sarcosine (N-methyl-glycine, Sar) — is a well-validated peptidomimetic strategy that abolishes POP substrate recognition by sterically occluding the active-site serine, preventing formation of the acyl-enzyme intermediate. Sarcosine is the minimal N-methylated residue: it retains the glycine Cα hydrogen, preserves backbone flexibility, maintains near-identical side-chain volume (one methyl group versus hydrogen), and is itself an endogenous CNS-active amino acid with established favorable ADME characteristics and no toxicological concern.

This fold is the second in a planned orthogonal stabilization strategy for Selank. Fold #8 addressed the C-terminus (pLDDT 0.90, PROMISING); Fold #18 addresses the interior backbone. The logical convergence is a dual-modified analogue combining both interventions — see Suggested Next Steps.

This distillation also parallels the logic applied to Semax in Fold #1, where N-terminal acetylation established a structural baseline for further analogue elaboration. The Selank series is building a similar iterative SAR narrative.

Predicted properties (where signal is moderate)

Structural interpretation: The sarcosine substitution does not perturb the predicted backbone conformation at the resolution of this prediction, consistent with sarcosine's near-isosteric character. The N-methyl group adds steric bulk to the amide nitrogen but does not introduce a new side-chain, preserving the compact geometry of the PGP turn. The slight pLDDT reduction relative to Fold #8 (0.87 vs. 0.90) may reflect marginally increased local conformational uncertainty introduced by N-methylation, or may simply reflect run-to-run variation in single-chain heptapeptide predictions — the difference is not interpretable as a meaningful signal.

What would strengthen this signal

Computational priorities:

1. Ensemble prediction — run multiple Boltz-2 seeds and Chai-1 for [Sar6]-Selank to assess conformational reproducibility and establish whether the turn geometry is genuinely stable or a single-run artifact.
2. Dual-modified analogue — predict [Sar6]-Selank-NH2 (combining Fold #8 amidation and Fold #18 sarcosine) to assess whether dual modification preserves structural integrity and to establish the next fold in this series.
3. Receptor complex modeling — if a GABA-A allosteric binding site model becomes available, dock [Sar6]-Selank to assess whether backbone N-methylation at position 6 disrupts the conformational presentation required for allosteric engagement.
4. POP cleavage site mapping — molecular docking of native Selank and [Sar6]-Selank into the POP active site (PDB: 1QFM or similar) to directly assess whether sarcosine sterically occludes the catalytic serine.

Wet-lab priorities (in order of mechanistic necessity):

1. Synthesize [Sar6]-Selank and confirm identity/purity by HPLC-MS.
2. POP cleavage assay — incubate native Selank and [Sar6]-Selank with purified porcine or recombinant human POP; quantify cleavage products by LC-MS over time. This directly tests the core hypothesis and fills the most critical literature gap.
3. Plasma stability assay — incubate both peptides in rat or human plasma; compare half-lives by LC-MS. Compare with Fold #8 Selank-NH2 to map orthogonal contributions.
4. GABA-A allosteric assay — replicate the gene-expression paradigm from PMID:28293190 (IMR-32 cells, GABA co-treatment) with [Sar6]-Selank to verify that allosteric modulation is preserved.
5. Behavioral pharmacology — if in vitro data are supportive, test [Sar6]-Selank in the elevated plus maze anxiolytic paradigm used for native Selank validation.

Mandatory disclaimer: All structural, stability, and property predictions in this report are in silico estimates from a single Boltz-2 prediction run. No synthesis, stability measurement, receptor binding assay, or in vivo experiment has been conducted. Predicted properties are computational approximations and may not reflect real-world biological behavior. This report is exploratory research only and constitutes no medical advice, therapeutic claim, or product endorsement.